Targeting HOX and PBX transcription factors in ovarian cancer

0Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

Backgound: Ovarian cancer still has a relatively poor prognosis due to the frequent occurrence of drug resistance, making the identification of new therapeutic targets an important goal. We have studied the role of HOX genes in the survival and proliferation of ovarian cancer cells. These are a family of homeodomain-containing transcription factors that determine cell and tissue identity in the early embryo, and have an anti-apoptotic role in a number of malignancies including lung and renal cancer.Methods: We used QPCR to determine HOX gene expression in normal ovary and in the ovarian cancer cell lines SK-OV3 and OV-90. We used a short peptide, HXR9, to disrupt the formation of HOX/PBX dimers and alter transcriptional regulation by HOX proteins.Results: In this study we show that the ovarian cancer derived line SK-OV3, but not OV-90, exhibits highly dysregulated expression of members of the HOX gene family. Disrupting the interaction between HOX proteins and their co-factor PBX induces apoptosis in SK-OV3 cells and retards tumour growth in vivo.Conclusion: HOX/PBX binding is a potential target in ovarian cancer. © 2010 Morgan et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Morgan, R., Plowright, L., Harrington, K. J., Michael, A., & Pandha, H. S. (2010). Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer, 10. https://doi.org/10.1186/1471-2407-10-89

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free